Mireille Favier1, Fabienne Le Goc-Sager2, Isabelle Vincent-Cantini3, Vincent Launay4, Eric-Alban Giroux5, Katia Lièvremont6, Isabelle Bonnet7, Catherine Barbe8, Eléa Duval9, Nathanael Loric9, Catherine Delbaldo10. 1. Centre hospitalier universitaire Caremeau, pharmacie, 4, rue du Professeur-Robert-Debré, 30029 Nîmes, France. Electronic address: mireille.favier@chu-nimes.fr. 2. Centre hospitalier de Cornouaille, hôpital Laënnec, service d'oncologie médicale et d'hématologie, 14, bis avenue Yves-Thépot, 29107 Quimper, France. 3. Polyclinique Bordeaux-Nord Aquitaine, pharmacie, 15-35, rue Claude-Boucher, 33300 Bordeaux, France. 4. Centre hospitalier Yves-Le-Foll, service d'hématologie-oncologie, 10, rue Marcel-Proust, 22000 Saint-Brieuc, France. 5. Institut de cancérologie de la Loire, 108, bis avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. 6. Polyclinique de Gentilly, 2, rue Marie-Marvingt, 54100 Nancy, France. 7. Hôpital Jean-Bernard, service d'oncologie, avenue Desandrouin, 59322 Valenciennes, France. 8. Centre hospitalier universitaire de Tours, service de cancérologie, 37044 Tours cedex 9, France. 9. CMI Stratégies, 80, rue Gallieni, 92100 Boulogne-Billancourt, France. 10. Hôpital des Diaconesses-Croix-Saint-Simon, service d'oncologie, 125, rue d'Avron, 75020 Paris France.
Abstract
INTRODUCTION: New pharmaceutical forms of trastuzumab and rituximab which can be administered by the subcutaneous route have been developed recently. For day hospitalisation units, these can be used in simpler treatment protocols than previous intravenous formulations. The objective of this study was to evaluate the medical and economic consequences of switching to subcutaneous formulations of trastuzumab and rituximab. METHODS: Thirty-six day care units in 30 hospitals or clinics participated in this observational study. Data were collected on the capacity of the units, the number of chemotherapy sessions implemented, the duration of occupation of a chair and the production capacity of the unit pharmacy. The number of additional sessions made possible by the use of subcutaneous forms in 2016 was determined and the associated gain in earnings calculated using national tariffs. RESULTS: Compared to the intravenous route, the mean duration of occupation of a chair was reduced by 56.1 % for a session of subcutaneous trastuzumab and by 73.8 % for a session of subcutaneous rituximab. The mean number of additional sessions made possible by the use of subcutaneous treatments was 242 [168-316] sessions by year by unit, corresponding to 2.7 % [1.9 %-3.4 %] of the total number of chemotherapy sessions in the unit. The corresponding gain in annual earnings was € 111 388. DISCUSSION: Switching the route of administration from the intravenous to the subcutaneous route is a useful strategy to address the increase in activity of day hospitalisation units. This allows an increase of 2.7 % in the total number of chemotherapy sessions in the unit. In most of the participating units, there was room for further optimization of activity, potentially to reach 4.2 % of the total number of sessions.
INTRODUCTION: New pharmaceutical forms of trastuzumab and rituximab which can be administered by the subcutaneous route have been developed recently. For day hospitalisation units, these can be used in simpler treatment protocols than previous intravenous formulations. The objective of this study was to evaluate the medical and economic consequences of switching to subcutaneous formulations of trastuzumab and rituximab. METHODS: Thirty-six day care units in 30 hospitals or clinics participated in this observational study. Data were collected on the capacity of the units, the number of chemotherapy sessions implemented, the duration of occupation of a chair and the production capacity of the unit pharmacy. The number of additional sessions made possible by the use of subcutaneous forms in 2016 was determined and the associated gain in earnings calculated using national tariffs. RESULTS: Compared to the intravenous route, the mean duration of occupation of a chair was reduced by 56.1 % for a session of subcutaneous trastuzumab and by 73.8 % for a session of subcutaneous rituximab. The mean number of additional sessions made possible by the use of subcutaneous treatments was 242 [168-316] sessions by year by unit, corresponding to 2.7 % [1.9 %-3.4 %] of the total number of chemotherapy sessions in the unit. The corresponding gain in annual earnings was € 111 388. DISCUSSION: Switching the route of administration from the intravenous to the subcutaneous route is a useful strategy to address the increase in activity of day hospitalisation units. This allows an increase of 2.7 % in the total number of chemotherapy sessions in the unit. In most of the participating units, there was room for further optimization of activity, potentially to reach 4.2 % of the total number of sessions.
Authors: María Reyes Abad-Sazatornil; Ainhoa Arenaza; Juan Bayo; Jesus García Mata; José María Guinea De Castro; Josefa León; Javier Letellez; Virginia Reguero; Carmen Martínez Chamorro; Antonio Salar Journal: BMC Health Serv Res Date: 2021-04-08 Impact factor: 2.655
Authors: Michael J Harvey; Yi Zhong; Eric Morris; Jacob N Beverage; Robert S Epstein; Anita J Chawla Journal: PLoS One Date: 2022-01-24 Impact factor: 3.240